Home › Lymphedema › NCT07012642
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: Adults 18 years or older with unilateral upper or lower extremity lymphedema Limb volume \> 5% BMI =\> 23 Oncology clearance if there is a cancer history Exclusion Criteria: Moderate to severe venous insufficiency Actively using GLP-1 RAs Known intolerance or adverse effect to GLP-1 RAs Medical history or morbidity where GLP-1 RAs are contraindicated as per patient's primary care provider such as MEN syndrome or history of thyroid cancer.
About the study
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedema patients, thereby addressing a critical gap in literature and potentially offering a new treatment option.
What is being tested
- GLP-1 Receptor Agonists (drug)
Sponsor: Advanced Reconstructive Surgery Alliance · Participants: 110 · Started: Apr 9, 2025
Contact the study team
- Giana Truax · Phone: 866-266-2577
- Saba Tasawar · Phone: 732-741-0970
Official record on ClinicalTrials.gov — NCT07012642
Locations in the U.S.
| New Jersey | River Center, Red Bank 260 Old Hook Rd Suite 304, Westwood |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.